References
  1. Pace D. Leishmanasis. J Infect. 2014; 69(1):10-18.
  2. Firooz A, Mortazavi H, Khamesipour A, Ghiasi M, Abedini R, Balighi K, et al. Old World cutaneous leishmaniasis in Iran: clinical variants and treatments. J Dermatolog Treat. 2020; 8:1-11.
  3. Van Griensven J, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect. 2014;20(4):286-299.
  4. Liese J, Schleicher U, Bogdan C. The innate immune response against Leishmania parasites. Immunobiology. 2008;213(3-4):377-387.
  5. Català A, Roé E, Dalmau J, Pomar V, Muñoz C, Yelamos O, et al. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature. Dermatology. 2015; 230: 204–207.
  6. Chichester AV, dos Reis AL, Castanheira AT, da Silva Nascimento CV, Biasi BH, Lodi VJ, et al. American Cutaneous Leishmaniasis: A Pleomorphic Disease with Unusual Clinical Presentations-Report of Three Cases. Int Arch Med. 2020 Jan 19;13. doi: 10.3823/2617
  7. Zandieh A, Zandieh B, Dastgheib L. Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review. Int J Dermatol. 2013;52(1):59-62.
  8. Golino A, Duncan JM, Zeluff B, DePriest J, McAllister HA, Radovancevic B, et al. Leishmaniasis in a heart transplant patient. J Heart Lung Transplant. 1992; 11(4 Pt 1):820-823.
  9. Mirzabeigi M, Farooq U, Baraniak S, Dowdy L, Ciancio G, Vincek V. Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient. J Cutan Pathol. 2006 Oct;33(10):701-704.
  10. Jafari S, Hajiabdolbaghi M, Mohebali M, Hajjaran H, Hashemian H. Disseminated leishmaniasis caused by Leishmania tropica in HIV-positive patients in the Islamic Republic of Iran. Eastern Mediterranean Health Journal. 2010;16(3):340-343
  11. Alcover MM, Rocamora V, Guillén MC, Berenguer D, Cuadrado M, Riera C, et al. Case report: diffuse cutaneous leishmaniasis by Leishmania infantum in a patient undergoing immunosuppressive therapy: risk status in an endemic Mediterranean area. Am J Trop Med Hyg. 2018;98(5):1313-1316.
  12. Tuon FF, Sabbaga Amato V, Floeter‐Winter LM, De Andrade Zampieri R, Amato Neto V, Siqueira França FO, et al. Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids–first report. Int J Dermatol. 2007;46(6):628-630.
  13. Darcis G, Van der Auwera G, Giot JB, Hayette MP, Tassin F, Estrada JA, et al. Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy. BMC Infect Dis. 2017 Dec 1;17(1):478.
  14. Firooz A, Khatami A, Khamesipour A, Nassiri-Kashani M, Behnia F, Nilforoushzadeh M, et al. Intralesional injection of 2% zinc sulfate solution in the treatment of acute Old World cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial. J Drug Dermatol. 2005; 4:73–77.
  15. Zerehsaz F, Salmanpour R, Handjani F, Ardehali S, Panjehshahin MR, Tabei SZ, et al. A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran. Int J Dermatol. 1999; 38:610–612.